SCHEMBL6533938

SCHEMBL6533938

COC(=O)c1cccc(OCC(O)CO)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.64
TSHR P16473 1/20 0.64
KDM4E B2RXH2 2/20 0.62
SMN1; SMN2 Q16637 3/20 0.57
LMNA P02545 2/20 0.57
USP2 O75604 1/20 0.57
HSD17B10 Q99714 1/20 0.57
PRMT5 O14744 1/20 0.52
WDR77 Q9BQA1 1/20 0.52
MRGPRX4 Q96LA9 1/20 0.50
TP53 P04637 1/20 0.50
ADRB2 P07550 2/20 0.49
ADRB1 P08588 2/20 0.49
ADRB3 P13945 2/20 0.49
ABCB1 P08183 2/20 0.49
CYSLTR1 Q9Y271 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP4F2 P78329 1/20 0.49
CYP4A11 Q02928 1/20 0.49
NPC1 O15118 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7988758 0.89 KDM4E (0.62) MAPK1TSHRKDM4ESMN1; SMN2LMNA
SCHEMBL14896697 0.86 KDM4E (0.53) MAPK1TSHRKDM4ESMN1; SMN2LMNA
SCHEMBL1587023 0.84 LMNA (0.54) MAPK1TSHRKDM4ELMNAALDH1A1
SCHEMBL1587028 0.84 LMNA (0.54) MAPK1TSHRKDM4ELMNAALDH1A1
SCHEMBL1587026 0.84 LMNA (0.54) MAPK1TSHRKDM4ELMNAALDH1A1
SCHEMBL26049008 0.84 NR1H4 (0.60) MAPK1TSHRKDM4ESMN1; SMN2LMNA
SCHEMBL28028400 0.82 MRGPRX4 (0.56) MAPK1KDM4ESMN1; SMN2LMNAUSP2
SCHEMBL10884593 0.82 TSHR (0.59) MAPK1TSHRKDM4EPRMT5WDR77
SCHEMBL28317169 0.82 LMNA (0.68) TSHRLMNAALDH1A1POLBRAB9A
SCHEMBL3529362 0.82 KDM4E (0.55) MAPK1KDM4ESMN1; SMN2LMNAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887863-B2 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES (US) 2005-05-03 US disclosed
EP-1272456-B1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2004-10-27 EP disclosed
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBVIE INC. 2004-08-26 US disclosed
EP-1272456-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS Abbott Laboratories (US) 2003-01-08 EP disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 US disclosed
WO-2001079157-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP MAPK1 3104/4885TSHR 4312/4885KDM4E 1796/4885
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP MAPK1 3104/4885TSHR 4312/4885KDM4E 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.